Telix Pharmaceuticals is exploding higher today following the announcement that the U.S. Food and Drug Administration approved Pixclara, the company's new amino acid PET imaging agent for diagnosing brain cancer. This regulatory milestone, which was announced in the early hours of September 14, serves as the primary catalyst for the stock's move to a new 52-week high of $13.11. The positive momentum follows the company's recent presentation at the Morgan Stanley 24th Annual Global Healthcare Conference, where management provided further insight into their clinical pipeline.